Sub-Total: $0.00
Have questions about this assay kit?
Panel of Human RXR Reporter Assays: RXRa, RXRb & RXRg
Product Description and Product Data
INDIGO’s Retinoid X Receptors Panel (RXR alpha, RXR beta, and RXR gamma) assay kit is an all-inclusive firefly luciferase reporter assay system that includes in addition to reporter cells for each RXR, optimized cell culture medium, a medium for diluting test compounds, a control agonist for each RXR, stable-glow luciferase detection reagent, detailed protocol, Protocol Quick Guide, and a cell culture-ready assay plate in strip-well format so that (if preferred) RXR alpha, RXR beta, and RXR gamma assays may be performed at different times. This panel contains sufficient materials to perform 32 RXR alpha assays, 32 RXR beta assays, and 32 RXR gamma assays in 96-well plate format.
Features
Clear, Reproducible Results
- All-Inclusive Assay Systems
- Exceptional Cell Viability Post-Thaw
- Consistent Results Lot to Lot
Product Specifications
| Target Type | Nuclear Hormone Receptor | ||
| Species | Human | ||
| Receptor Form | Hybrid | ||
| Assay Mode | Agonist, Antagonist | ||
| Kit Components |
| ||
| Shelf Life | 6 months | ||
| Orthologs Available | No | ||
| Shipping Requirements | Dry Ice | ||
| Storage temperature | -80C |
Data
Target Background
Retinoid X receptors (RXRs) and retinoic acid receptors (RARs), are nuclear receptors that mediate the biological effects of retinoids by their involvement in retinoic acid-mediated gene activation. These receptors exert their action by binding, as homodimers or heterodimers, to specific sequences in the promoters of target genes and regulating their transcription. The protein encoded by this gene is a member of the steroid and thyroid hormone receptor superfamily of transcription factors.
This PANEL of Retinoid X Receptors Reporter Assays utilizes non-human mammalian cells engineered to express distinct human RXRα (NR2B1), RXRβ (NR2B2), and RXRγ (NR2B3) proteins.
Product Documentation
Citations
Retinoid‐based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non‐specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may address these shortcomings.
Repurposing of existing cancer drugs to overcome their physical limitations, such as insolubility, represents an attractive strategy to achieve enhanced therapeutic efficacy and broaden the range of clinical applications. Such an approach also promises to offer substantial cost savings in drug development efforts. Here we use repurposed FDA-approved topical agent bexarotene (Targretin™), currently in limited use for cutaneous manifestations of T-cell lymphomas, and re-engineer it for use in solid tumor applications by forming self-assembling nanobubbles. Physicochemical characterization studies of the novel prodrug nanobubbles demonstrated their stability, enhanced target cell-internalization capability and highly controlled release profile in response to application of focused ultrasound energy. Using an in vitro model of hepatocellular carcinoma and an in vivo large animal model of liver ablation, we demonstrate the effectiveness of bexarotene prodrug nanobubbles when used in conjunction with catheter-based ultrasound, thereby highlighting the therapeutic promise of this trimodal approach.
Also available as a service
